StockData

Seres Therapeutics vs Cartesian Therapeutics

MCRB and RNAC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MCRB and RNAC compare

Cartesian Therapeutics is the larger company, worth 14 times as much as Seres Therapeutics ($192M against $14.0M).

Seres Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1193% compared with −10284% at Cartesian Therapeutics.

Seres Therapeutics scores higher on the StockData Score (6 against 1 for Cartesian Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMCRBRNAC
Size and price
Market cap$14.0M$192M
Share price$1.41$6.35
Change, 1 year−91.6%−16.2%
Change, 5 years−99.2%−93.4%
Beta (5Y)0.28–
Employees6675
StockData Score
Total score6 (better)1
Valuation score1 (better)0
Growth score00
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S7.4× (better)130×
P/B0.4×–
FCF yield−366%−40.9% (better)
Growth
Revenue growth, 5Y average−52.7%−30.0% (better)
Net income growth (TTM)−126%–
EPS growth (TTM)−121%–
Profitability
Operating margin−4463% (better)−10519%
Net margin−1193% (better)−10284%
FCF margin−2724% (better)−5322%
Return on equity−66.6%–
Financial health
Debt / equity0.00–
Current ratio2.117.48 (better)
Altman Z-score−15.93−4.56 (better)
Piotroski F-score6 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions22.9%29.3%
Held by insiders2.3%55.7%
Insider net buying, 12 months−$10.0K (better)−$52.9K
Short interest, % of float3.5%14.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.